NO20011211L - Multippel enhet for kontrollert mateffektuavhengig frigivelse av farmasöytiske preparater og fremgangsmåter for fremstilling avsamme - Google Patents

Multippel enhet for kontrollert mateffektuavhengig frigivelse av farmasöytiske preparater og fremgangsmåter for fremstilling avsamme

Info

Publication number
NO20011211L
NO20011211L NO20011211A NO20011211A NO20011211L NO 20011211 L NO20011211 L NO 20011211L NO 20011211 A NO20011211 A NO 20011211A NO 20011211 A NO20011211 A NO 20011211A NO 20011211 L NO20011211 L NO 20011211L
Authority
NO
Norway
Prior art keywords
methods
pharmaceutical preparations
multiple unit
food effect
dependent release
Prior art date
Application number
NO20011211A
Other languages
English (en)
Other versions
NO20011211D0 (no
Inventor
Venkata-Rangarao Kanikanti
Roland Rupp Haferbusch
Erich Brendel
Claus Weisemann
Ernst Chantraine
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO20011211L publication Critical patent/NO20011211L/no
Publication of NO20011211D0 publication Critical patent/NO20011211D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nonmetallic Welding Materials (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

Foreliggende oppfinnelse angår oralt administrerbare multi-enhets vedvarende frigivelses doseformer som har kontrollert agitasjonsuavhengig frigivelse av aktiv forbindelse og fremgangsmåter for deres fremstilling ved anvendelse av en utvalgt eroderbar hydrofil polymer (HPC) og en begrensning av maksimumstørrelsen for aktiv forbindelse-inneholdende polymerpartikler på < 3 mm.
NO20011211A 1998-09-18 2001-03-09 Multippel enhet for kontrollert mateffektuavhengig frigivelse av farmasøytiske preparater og fremgangsmÕter for fremstilling av samme NO20011211D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19842753A DE19842753A1 (de) 1998-09-18 1998-09-18 Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
PCT/EP1999/006882 WO2000016748A1 (de) 1998-09-18 1999-09-17 Agitationsunabhängige pharmazeutische multiple-unit-retardzubereitungen und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
NO20011211L true NO20011211L (no) 2001-03-09
NO20011211D0 NO20011211D0 (no) 2001-03-09

Family

ID=7881376

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011211A NO20011211D0 (no) 1998-09-18 2001-03-09 Multippel enhet for kontrollert mateffektuavhengig frigivelse av farmasøytiske preparater og fremgangsmÕter for fremstilling av samme

Country Status (29)

Country Link
US (1) US6805881B1 (no)
EP (1) EP1113787B1 (no)
JP (1) JP2002526437A (no)
KR (1) KR100660072B1 (no)
CN (1) CN1178650C (no)
AT (1) ATE260645T1 (no)
AU (2) AU5861499A (no)
BG (1) BG105325A (no)
BR (1) BR9913839A (no)
CA (1) CA2344372C (no)
DE (2) DE19842753A1 (no)
DK (1) DK1113787T3 (no)
EE (1) EE04700B1 (no)
ES (1) ES2215404T3 (no)
HK (1) HK1040932B (no)
HR (1) HRP20010198A2 (no)
HU (1) HUP0103669A3 (no)
ID (1) ID28735A (no)
IL (2) IL141532A0 (no)
NO (1) NO20011211D0 (no)
NZ (1) NZ510563A (no)
PL (1) PL195543B1 (no)
PT (1) PT1113787E (no)
RU (1) RU2235540C2 (no)
SK (1) SK285099B6 (no)
TR (1) TR200100756T2 (no)
UA (1) UA73097C2 (no)
WO (2) WO2000016747A1 (no)
ZA (1) ZA200101485B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
AR034813A1 (es) † 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
RU2401125C2 (ru) 2004-12-27 2010-10-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ стабилизации лекарственного средства против деменции
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005012561B4 (de) 2005-03-18 2008-06-19 Christian Beer Verfahren zum Betrieb eines Werkstück-Transfersystems
DE102005045518A1 (de) * 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
CA2624310C (en) 2005-10-04 2014-01-07 Bayer Healthcare Ag Polymorphic form of 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
CN100448432C (zh) * 2006-10-26 2009-01-07 徐竹青 高溶出度尼莫地平分散片的制备方法
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
US7952167B2 (en) * 2007-04-27 2011-05-31 Taiwan Semiconductor Manufacturing Company, Ltd. Scribe line layout design
ES2525648T3 (es) * 2009-01-28 2014-12-26 Novartis Ag Formulaciones galénicas que comprenden Aliskiren
US20100247646A1 (en) * 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Extended release tablets of nisoldipine
TR201802207T4 (tr) 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5482525A (en) 1977-12-13 1979-06-30 Aisan Ind Co Ltd Exhaust gas recirculation system
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4449983A (en) 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
JPH03145418A (ja) 1989-10-27 1991-06-20 Sumitomo Pharmaceut Co Ltd 塩基性薬物塩酸塩の徐放性製剤
WO1992018106A1 (en) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Method of manufacturing solid dispersion
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
FR2725624B1 (fr) 1994-10-14 1997-01-17 Jouveinal Inst Rech Procede de preparation de formes pharmaceutiques a liberation controlee
DE19504831A1 (de) 1995-02-14 1996-09-05 Basf Ag Feste Wirkstoffzubereitungen enthaltend Hydroxypropylcellulose

Also Published As

Publication number Publication date
EE04700B1 (et) 2006-10-16
EP1113787B1 (de) 2004-03-03
CN1317959A (zh) 2001-10-17
US6805881B1 (en) 2004-10-19
TR200100756T2 (tr) 2001-07-23
AU750617B2 (en) 2002-07-25
WO2000016747A1 (de) 2000-03-30
SK285099B6 (sk) 2006-06-01
PT1113787E (pt) 2004-07-30
JP2002526437A (ja) 2002-08-20
ES2215404T3 (es) 2004-10-01
WO2000016748A1 (de) 2000-03-30
HRP20010198A2 (en) 2002-04-30
NZ510563A (en) 2002-10-25
DE59908764D1 (de) 2004-04-08
ZA200101485B (en) 2002-02-22
ATE260645T1 (de) 2004-03-15
AU5861499A (en) 2000-04-10
BG105325A (bg) 2001-11-30
PL346535A1 (en) 2002-02-11
DK1113787T3 (da) 2004-05-17
AU6191899A (en) 2000-04-10
UA73097C2 (en) 2005-06-15
DE19842753A1 (de) 2000-03-23
HK1040932B (zh) 2005-08-05
KR100660072B1 (ko) 2006-12-22
HUP0103669A3 (en) 2006-07-28
NO20011211D0 (no) 2001-03-09
BR9913839A (pt) 2001-06-12
IL141532A0 (en) 2002-03-10
ID28735A (id) 2001-06-28
EP1113787A1 (de) 2001-07-11
RU2235540C2 (ru) 2004-09-10
PL195543B1 (pl) 2007-09-28
KR20010073172A (ko) 2001-07-31
HK1040932A1 (en) 2002-06-28
IL141532A (en) 2007-03-08
SK3722001A3 (en) 2001-10-08
CA2344372C (en) 2009-12-22
CA2344372A1 (en) 2000-03-30
HUP0103669A2 (hu) 2002-01-28
CN1178650C (zh) 2004-12-08
EE200100161A (et) 2002-08-15

Similar Documents

Publication Publication Date Title
NO20011211L (no) Multippel enhet for kontrollert mateffektuavhengig frigivelse av farmasöytiske preparater og fremgangsmåter for fremstilling avsamme
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
DE69520768D1 (de) Pharmazeutische Zubereitungen, die Fluoxetin enthalten
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
NZ262569A (en) Reducing bone loss by administration of 3,4-diphenylbenzo[b]pyran derivatives
CA2394232A1 (en) Dual-release compositions of a cyclooxygenase-2-inhibitor
DE69620606D1 (de) Feste oral anzuwendende arzeneiform
HUP0104318A2 (hu) cGMP PDE-5 inhibitort tartalmazó szabályzottan hatóanyagot felszabadító gyógyászati készítmények
FR2771291B1 (fr) Spheroides, procede de preparation et compositions pharmaceutiques
MacPhail et al. Acyclovir-resistant, foscarnet-sensitive oral herpes simplex type 2 lesion in a patient with AIDS
CO5160287A1 (es) Formulacion de liberacion controlada de divalproex sodico
NO951498L (no) Farmasöytisk preparat for behandling av osteoporose
AR011919A1 (es) FORMULACIoN EN COMPRIMIDOS O CÁPSULAS PARA TRAGAR DE PARACETAMOL (N-ACETIL-P-AMINOFENOL) Y PROCEDIMIENTO PARA PREPARARLA
DK0758889T3 (da) Faste,farmaceutiske præparater, der indeholder (S)-2-(4-isobutylphenyl)propionsyre som aktiv bestanddel og mikrokrystallins
HUP0401429A2 (hu) Lumirakoxibot tartalmazó gyógyszerkészítmény
HUP0500842A2 (hu) Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra
BR9608392A (pt) Preparação multiparticulada de liberação controlada e forma de dosagem em tablete.
WO2005051350A3 (en) Water dispersible tablet
NO995685L (no) Nye glycosylerte ginkgolidderivater, anvendelse derav som medikamenter og farmasoeytiske blandinger
MA26788A1 (fr) COMPOSITIONS PHARMACEUTIQUES DESTINÉES à L&#39;ADMINISTRATION PAR VOIE ORALE DE PHLOROGLUCINOL ET LEUR PRÉPARATION
CA2255064A1 (en) Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
BRPI0307319B8 (pt) forma de dosagem oral para liberação controlada de droga e processo para sua preparação
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
AR015724A1 (es) La utilizacion de un inhibidor del intercambiador entre na+ y h+ para la preparacion de un medicamento destinado al tratamiento o a la profilaxia deenfermedades del sistema nervioso central.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application